Subutex

Subutex and Buprenorphine Treatment for Opioid Use Disorder

Subutex is a former brand name for a sublingual tablet containing buprenorphine without naloxone. Buprenorphine monoproducts are used in carefully managed treatment for opioid use disorder. They are not ADHD medicines, general pain relievers or prescription-free detox products.

In the United States, the original branded Subutex product is discontinued, although FDA-approved generic buprenorphine sublingual tablets remain available. A current prescription may therefore say buprenorphine rather than Subutex. The exact product, strength and phase of treatment should be confirmed with the prescriber and dispensing pharmacist.

Category correction: move this page from /adhd/subutex/ to an opioid-use-disorder or addiction-treatment category and apply a 301 redirect. Keeping it under ADHD is medically inaccurate and can create serious search-intent and patient-safety problems.

• Active ingredient: buprenorphine.
• Clinical role: treatment of opioid dependence or opioid use disorder as part of a complete plan.
• Form discussed here: sublingual buprenorphine without naloxone.
• Controlled status: Schedule III in the United States.
• Major risks: respiratory depression, misuse, precipitated withdrawal, interactions and accidental pediatric exposure.

Why Buprenorphine Is Used in OUD Care

Buprenorphine is a partial opioid agonist. When appropriately prescribed, it can reduce withdrawal symptoms and craving, stabilize opioid receptors and support a return to safer daily functioning. Treatment can reduce illicit opioid use and overdose risk, but no medicine makes a person immune to overdose.

Medication is most effective as part of comprehensive care. That may include counseling, peer support, treatment of depression or trauma, infectious-disease services, recovery planning, housing support and attention to pain. Lack of access to counseling should not automatically be used to withhold indicated medication, but the care team should still offer appropriate support.

Success is not defined only by a negative drug test. It can include fewer overdoses, reduced high-risk use, stable housing, improved relationships, engagement with care and better physical and mental health.

Subutex Is Not an ADHD Treatment

Buprenorphine is not approved to treat inattention, impulsivity or hyperactivity. Opioid withdrawal, intoxication, sleep loss, anxiety and depression can all impair concentration, but treating OUD is not the same as treating ADHD.

A person with both conditions needs coordinated assessment. Stimulants, non-stimulants and opioid-use-disorder medicines have different interaction, misuse and monitoring considerations. Do not position Subutex as a focus enhancer or combine it with another person’s ADHD prescription.

Correcting the Existing Catalog

1. Remove ADHD from the product title, description, breadcrumbs and internal links.
2. Update the category to opioid use disorder or addiction treatment.
3. Use “buprenorphine monoproduct” when discussing current generic dispensing.
4. Do not imply that the discontinued U.S. brand is still routinely supplied as branded Subutex.
5. Redirect the old URL and update the sitemap, menus and canonical URL.

Induction Requires the Right Clinical Timing

Starting buprenorphine too soon after another opioid can trigger precipitated withdrawal. Buprenorphine binds strongly to opioid receptors and can displace a full opioid agonist. The timing depends on the opioid used, the time since the last use, the presence of objective withdrawal and individual factors.

This is especially important in the fentanyl era because exposure and withdrawal patterns may be unpredictable. A clinician may use a standard observed or home induction plan, or another protocol when clinically appropriate. A website should not provide a one-size-fits-all start time or encourage a person to experiment with tablets.

What an Induction Plan Should Clarify

• Which opioid was used, by what route and when it was last used.
• Whether methadone, fentanyl or a long-acting opioid is involved.
• How withdrawal will be assessed.
• Who to contact if symptoms rapidly worsen.
• When emergency care is required.
• How the person will obtain the next scheduled prescription and follow-up.

Severe agitation, vomiting, diarrhea, dehydration or sudden worsening after an initial dose requires prompt contact with the treatment team. Do not take repeated extra doses without explicit instructions.

Buprenorphine Alone Versus Buprenorphine with Naloxone

Buprenorphine monoproduct contains no naloxone. Combination products contain both buprenorphine and naloxone. Current labeling often prefers the monoproduct for induction, while a combination product may be preferred for ongoing unsupervised administration when clinically appropriate because naloxone can discourage certain forms of misuse.

This is not a rule that every patient must follow. Pregnancy, intolerance, observed administration, clinical history, availability and local practice may affect the choice. A prescriber should document why a monoproduct is suitable for ongoing treatment.

Do not switch tablet-for-tablet between products or formulations. Films, tablets, injections and implants have different instructions and may not be directly interchangeable.

Strengths and Patient-Specific Directions

Buprenorphine sublingual monoproduct tablets have commonly been labeled in 2 mg and 8 mg strengths. The existence of a strength does not establish the correct daily amount. Induction, stabilization and maintenance are different clinical phases.

Follow the exact pharmacy label and prescriber instructions. Sublingual tablets are intended to dissolve under the tongue; swallowing or chewing them can change absorption. Do not cut, crush, inject, snort or share a tablet. Manipulating the product can cause overdose, infection, withdrawal or death.

Missed Doses and Treatment Gaps

After a treatment gap, opioid tolerance and withdrawal status may have changed. Contact the prescriber rather than restarting an old amount automatically. Taking a full previous amount after loss of tolerance or combining it with illicit opioids can be dangerous.

A refill problem should be addressed early. Keep clinic and pharmacy contact information available, know weekend procedures and request routine refills before the last dose when permitted.

Respiratory Depression, Sedation and Overdose Risk

Buprenorphine can cause life-threatening respiratory depression, particularly when it is misused or combined with alcohol, benzodiazepines, sedatives, gabapentinoids, other opioids or illicit substances. A partial-agonist ceiling effect does not eliminate overdose risk.

Warning signs include very slow or shallow breathing, blue or gray lips, pinpoint pupils, inability to wake, choking or gurgling sounds and extreme limpness. Treat suspected overdose as an emergency. Call emergency services, give naloxone when available and trained to do so, and provide rescue breathing if instructed.

Because buprenorphine can last longer than naloxone, the person may become sedated again after an initial response. Emergency observation is still required.

Alcohol, Benzodiazepines and Other CNS Depressants

Combining buprenorphine with alcohol or central nervous system depressants can cause profound sedation, respiratory depression, coma and death. Tell the OUD prescriber about clonazepam, alprazolam, diazepam, lorazepam, sleeping pills, muscle relaxants, gabapentin, pregabalin and sedating antihistamines.

FDA guidance emphasizes that buprenorphine treatment should not automatically be withheld from a patient taking a benzodiazepine or another CNS depressant, because untreated OUD also carries serious risk. The correct response is coordinated care, risk reduction, medication verification and close monitoring—not secrecy or abrupt unsupervised discontinuation.

• Use one coordinated treatment plan whenever possible.
• Do not drink alcohol during treatment.
• Do not add a sleeping pill to manage induction discomfort without approval.
• Store naloxone where household members can reach it.
• Teach close contacts how to recognize and respond to overdose.

Discuss Naloxone with Every OUD Treatment Plan

Naloxone is an opioid-overdose reversal medicine. Patients receiving medicines for OUD should discuss obtaining it for home use, and people around them should know where it is stored and how to administer it.

Naloxone does not replace emergency services. More than one dose may be needed, especially with potent opioids or prolonged buprenorphine effects. After administration, remain with the person, follow dispatcher instructions and watch for recurring sedation.

Replace naloxone before it expires and after it is used. Keep it accessible rather than locked in the same container as the controlled medicine.

Misuse, Diversion and Safe Accountability

Buprenorphine is a Schedule III controlled substance with misuse and diversion potential. Diversion can harm a child, an opioid-naive adult or a person combining it with sedatives. Treatment programs may use prescription monitoring, toxicology, pill counts or shorter refill intervals when clinically justified.

Accountability should support treatment rather than shame the patient. Unexpected results can reflect relapse, contamination, misunderstanding or a change in circumstances. A clinician should investigate and adjust the safety plan.

Never sell, trade or share a dose. Do not post tablet photos, quantities or pickup information on social media. Report a lost or stolen prescription promptly according to clinic and local requirements.

Accidental Exposure Is a Medical Emergency

Even one tablet can cause severe or fatal respiratory depression in a child or opioid-naive person. Store buprenorphine in the original child-resistant pharmacy container, secured in a location that children, visitors and pets cannot access.

Do not leave tablets in a pocket, vehicle, bedside drawer, purse or unmarked organizer. Count doses in a private area and immediately secure the container. If accidental ingestion is possible, call emergency services and poison control without waiting for symptoms.

Dental Care for Medicines Dissolved in the Mouth

FDA has warned about dental problems with buprenorphine products that dissolve in the mouth, including cavities, infection, erosion and tooth loss. These events have occurred even in people without a previous dental history. The benefits of buprenorphine for OUD still outweigh these risks, and oral care can reduce harm.

After the medicine has completely dissolved, take a large sip of water, swish gently around the teeth and gums, and swallow. Wait at least one hour before brushing to reduce potential damage. Arrange a dental visit soon after starting and tell the dentist about transmucosal buprenorphine.

Report tooth pain, sensitivity, broken fillings, gum swelling or signs of infection. Do not stop OUD treatment because of a dental problem without coordinating medical and dental care.

Liver, Adrenal and Other Important Medical Risks

Buprenorphine has been associated with liver-related events. Baseline and periodic liver testing may be appropriate, especially with hepatitis, alcohol use or other hepatotoxic medicines. Report dark urine, jaundice, persistent right-upper abdominal pain or unexplained severe fatigue.

Opioids can affect adrenal function. Persistent nausea, vomiting, loss of appetite, unusual weakness, dizziness or low blood pressure may require assessment. Buprenorphine can also cause orthostatic hypotension, so rise carefully until its effects are known.

Headache, nausea, constipation, sweating, sleep disturbance and pain are among reported effects. Severe symptoms, dehydration or inability to function should be reviewed rather than treated with unapproved extra medicines.

Dependence, Withdrawal and Discontinuation

Physical dependence can develop during ongoing buprenorphine treatment. That is not the same as uncontrolled addiction, but abrupt discontinuation can cause withdrawal and increase relapse and overdose risk.

There is no universal deadline for ending OUD medication. Some patients benefit from long-term treatment. A taper, if chosen, should be gradual and collaborative, with monitoring, naloxone, relapse prevention and rapid access to restart treatment when needed.

After stopping, tolerance to full opioids can be lower. Returning to a previously used amount can be fatal. Overdose-prevention counseling remains essential during and after any taper.

Pregnancy, Breastfeeding and Newborn Considerations

Untreated OUD during pregnancy creates major risks, and buprenorphine may be part of appropriate prenatal treatment. Product choice, formulation and monitoring should be coordinated with obstetric and addiction-care professionals. Do not stop after a positive pregnancy test without urgent clinical guidance.

Long-term opioid exposure during pregnancy can result in neonatal opioid withdrawal syndrome, which is expected and treatable but requires planning. The delivery team should know about treatment so the newborn can be monitored.

Breastfeeding decisions depend on maternal stability, other substance use, infant health and current clinical guidance. Observe an infant for unusual sleepiness, feeding difficulty or breathing problems and seek urgent care when needed.

Drug Interactions Beyond Sedatives

Buprenorphine is affected by CYP3A4. Strong inhibitors can increase exposure, while strong inducers can reduce exposure or contribute to withdrawal. Some antiretrovirals, antifungals, antibiotics, seizure medicines and herbal products can matter.

Serotonergic medicines may contribute to serotonin syndrome when combined with opioids. Symptoms can include agitation, sweating, tremor, muscle rigidity, diarrhea and fever. The complete medicine list should include antidepressants, migraine medicines, linezolid and supplements.

Do not start or stop an interacting medicine without telling the OUD prescriber. A pharmacy using a complete profile can help identify conflicts across specialists.

Driving, Work and Safety-Sensitive Tasks

Buprenorphine can cause sleepiness, dizziness and slowed reaction, particularly during induction, dose changes or combination with other depressants. Do not drive or operate machinery until the prescriber has assessed the response and the patient knows how treatment affects alertness.

Workplace drug testing may detect prescribed buprenorphine on a targeted panel. Keep prescription documentation, but do not disclose more medical information than required. A clinician can help address safety-sensitive work without encouraging concealment.

Safe Telehealth and Online Buprenorphine Care

Telehealth can improve access to OUD treatment when it complies with current federal and state requirements. A legitimate service identifies the clinician, verifies patient location, reviews opioid history and other medicines, explains induction and provides emergency and follow-up procedures.

A website that simply sells “Subutex without prescription” is not a treatment program. Avoid sellers that promise guaranteed approval, request payment by cryptocurrency only, ship loose tablets or conceal the dispensing pharmacy.

• Verify the prescriber’s identity and professional license.
• Verify the dispensing pharmacy through the relevant state board.
• Confirm the active ingredient, strength, quantity and directions.
• Know who handles precipitated withdrawal, relapse and refill gaps.
• Keep a local emergency and naloxone plan even when visits are remote.

Authenticity, Storage and Disposal

Generic buprenorphine tablets can look different by manufacturer. Do not use appearance alone to judge authenticity. The pharmacist can verify the manufacturer, National Drug Code, lot and authorized supply chain.

Keep the medicine in its pharmacy-labeled child-resistant container, secured from children and visitors. Protect it from heat and moisture according to the exact label. Do not store it in a bathroom or hot vehicle.

Use a medicine take-back option when available and follow FDA or pharmacist instructions when one is not readily available. Because accidental exposure can be fatal, do not leave unwanted tablets in household trash where they can be recovered.

Maintaining OUD Treatment Through Setbacks

A return to opioid use does not mean treatment has failed. It signals the need to reassess dose adequacy, triggers, mental health, pain, housing, contamination risk and the level of support. Discharging a patient without a transition plan can increase overdose risk.

Keep appointments after a setback, tell the clinician what was used and carry naloxone. Fentanyl may be present in drugs sold as heroin, pain pills or stimulants. Toxicology results should inform safety rather than replace an honest clinical conversation.

Long-term continuity matters. Before travel or relocation, confirm prescribing rules, pharmacy availability and the amount legally supplied. Carry medication in the original labeled container.

Frequently Asked Questions About Subutex

What is Subutex?

Subutex is a discontinued U.S. brand name for sublingual buprenorphine without naloxone, used in treatment for opioid dependence or OUD.

Is generic Subutex available?

FDA-approved generic buprenorphine sublingual monoproduct tablets may be available even though the original brand is discontinued.

Is Subutex an ADHD medicine?

No. Buprenorphine is not approved for ADHD. The page should be moved out of the ADHD category.

Is buprenorphine an opioid?

Yes. It is a partial opioid agonist used therapeutically to treat OUD and carries opioid-related risks.

Is buprenorphine controlled?

Yes. Buprenorphine is a Schedule III controlled substance in the United States.

Why can starting Subutex cause withdrawal?

Starting while a full opioid agonist is still strongly affecting receptors can precipitate withdrawal, so induction timing requires clinical guidance.

What is the difference between Subutex and Suboxone?

Subutex contains buprenorphine alone, while Suboxone contains buprenorphine plus naloxone.

Can alcohol be used with buprenorphine?

No. Alcohol can add dangerous sedation and respiratory depression.

Can buprenorphine be combined with benzodiazepines?

The combination raises overdose risk and requires coordinated medical management. Do not hide or abruptly stop either prescription.

Should a person on buprenorphine have naloxone?

Yes. Discuss naloxone, keep it accessible and teach close contacts how to respond to an overdose.

Can buprenorphine harm teeth?

Products dissolved in the mouth have been associated with serious dental problems. Rinsing after dissolution and regular dental care are important.

Can a tablet be swallowed?

Sublingual tablets are designed to dissolve under the tongue. Follow the exact product instructions rather than chewing or swallowing them.

Can treatment be stopped suddenly?

Abrupt stopping can cause withdrawal and increase relapse and overdose risk. Any taper should be planned with the prescriber.

Can buprenorphine be used during pregnancy?

It may be used as part of specialist OUD care during pregnancy. Treatment should be coordinated with obstetric and addiction professionals.

What are overdose warning signs?

Slow or stopped breathing, inability to wake, blue or gray lips, pinpoint pupils and gurgling sounds require naloxone and emergency services.

Can Subutex be bought without a prescription?

No. A legitimate U.S. pharmacy requires a valid prescription and dispenses a traceable, patient-labeled product.

What if the medicine looks different?

Keep it separate and ask the dispensing pharmacist to verify the manufacturer, imprint, strength and supply record before taking it.

How should buprenorphine be stored?

Keep it secured in the original pharmacy container, protected as directed and completely inaccessible to children and unauthorized people.

Medical Disclaimer and Authoritative Sources

This page provides general education and does not diagnose opioid use disorder, direct an induction or replace a licensed prescriber, pharmacist or emergency service. Current labeling and the patient-specific treatment plan take priority. For suspected overdose, give naloxone when available and call emergency services immediately.

Sources Used for Medical Verification

• DailyMed: Buprenorphine sublingual tablet prescribing information
• SAMHSA: Buprenorphine treatment information
• FDA: Dental risks with buprenorphine dissolved in the mouth
• FDA: Discuss naloxone with patients receiving medicines for OUD
• FDA: Locate a state-licensed online pharmacy